It was a thrilling tale of will they, won’t they, but in the end Canada and the US agreed on a trade deal, which was signed today by Canada, the…
Tag: NAFTA
What the End of NAFTA Could Mean for Patent Filing Trends in Canada
According to the IP Canada Report 2016, the USA is the top patent filer in Canada, with 17,966 applications in 2015, immediately followed by Canada, with 4,277 applications.[1] In 2015,…
Eli Lilly v. Canada: Investor-State Arbitration Is an Open Gate for the “Patent Trolls”
In 2017, Canada won the dispute against the US-based pharmaceutical company Eli Lilly in investor-state arbitration (ISA). Foreign investors can sue sovereign governments in ISA in case of mistreatment, such…
in Canada, European Union, Infringement, IP, Jurisdiction, Patentability, Patents, Pharmaceutical Drugs, Regulatory Policy, Supreme Court of Canada, UK, UK, US, US-Canada Relations0by Editor
431
Sitting This One Out: SCC Refuses to Clarify “Promise of a Patent” Doctrine
Last month, the Supreme Court of Canada (SCC) denied leave to appeal in the case Eli Lilly Canada Inc v Novopharm Ltd, passing on an opportunity to clarify the controversial…
in Copyright, Copyright Reform, European Union, IP, IP Reform, Patents, Pharmaceutical Drugs, Supreme Court of Canada, Trademarks, US, US-Canada Relations, WIPO0by Editor
279
A Cautionary Kudos: Canada Moves Up on USTR IP Watch List
Earlier this month, the United States Trade Representative (USTR) released its annual “Special 301 Report,” which evaluates the intellectual property rights (IPR) protection and enforcement of its trading partners. Over…